Syndax Pharmaceuticals Grants Inducement Awards to New Employees

The biopharmaceutical company awarded stock options to 8 new hires under its 2023 Inducement Plan.

Apr. 3, 2026 at 8:30pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a group of polished metal and glass laboratory equipment arranged elegantly on a clean, white seamless background, conceptually representing the precision and innovation of Syndax's cancer research.

Syndax's strategic investment in new talent signals its dedication to advancing cutting-edge cancer therapies.NYC Today

Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company advancing innovative cancer therapies, announced that on April 1, 2026, it granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan.

Why it matters

The inducement grants are a common practice for publicly traded companies to attract and retain top talent in the highly competitive biopharmaceutical industry. These types of awards help align new employees' interests with those of the company and its shareholders.

The details

The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax.

On April 1, 2026, Syndax granted the inducement awards.

The players